Annalise.ai

What Annalise.ai does

Annalise.ai is an Australian clinician-led artificial intelligence company founded in 2019 and headquartered in Sydney, specializing in comprehensive AI solutions for medical imaging — primarily chest X-ray interpretation and non-contrast head CT analysis. The company's core product is an AI diagnostic platform that identifies 12 findings in under 90 seconds, integrating within existing clinical workflows to surface emergent and incidental findings for radiologist review. Underpinning this is the Harrison.Rad 1.5 radiology-specific foundation model, a proprietary next-generation architecture that supports the company's product portfolio. The technology operates as a computer vision and anomaly detection system, processing chest radiographs for disease detection including lung cancer screening and triage support.

The company operates as part of the broader Harrison.ai Radiology portfolio, with multiple AI solutions unified under the Harrison.ai brand. Annalise.ai's go-to-market is an enterprise B2B direct sales model targeting three primary customer segments: public hospitals and NHS trusts, private radiology providers, and private hospital networks. Pricing is quote-based and not publicly disclosed, consistent with large institutional contracts. The platform is deployed across 1,000+ sites spanning four continents and 40+ countries with regulatory clearance, used by 3,500 clinicians globally. Key institutional customers include NHS England (64 trusts covering 2.8 million chest X-rays annually), Gleneagles Hong Kong, Capital Health, Inland Imaging, Radiology Associates of North Texas, Manipal Hospitals, and Apollo Radiology, among others.

Revenue is generated through AI diagnostic software licensing to hospitals and radiology providers, with deployment via institutional procurement mechanisms including the NHS AI Diagnostic Fund. The company is backed by $240 million in total funding from leading global investors. Strategic partnerships include a 2025 data-sharing alliance with I-MED Radiology (Australia's largest diagnostic imaging network) for AI model training, validated by the Australian Privacy Commissioner. Reported customer outcomes include 45% improvement in diagnostic accuracy and 12% improvement in efficiency across NHS deployments, alongside documented reductions in patient wait times at UK and Norwegian hospital systems.

Name

Annalise.ai

Legal name

Annalise.ai

Website

https://annalise.ai

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Annalise.ai is an Australian clinician-led AI company developing medical imaging solutions, primarily chest X-ray interpretation and head CT analysis, sold via enterprise B2B licensing to public hospitals, private radiology providers, and hospital networks across 40+ countries.

Ownership category

akta.pro rank

Product category

Medical Imaging AI / Radiology Diagnostics

NAICS

Software Publishers (5132), Computer Systems Design and Related Services (54151), Diagnostic Imaging Centers (621512)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Computer Programming Services (7371)

akta.pro industry

PRIMARYHLAHABAJ

Radiology AI, CAD & Advanced Visualization Software

Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

SECONDARYHDAAAEAH

Medical Imaging AI

Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Computer Vision & Video Analytics

SECONDARYHLAAALAO

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLACALAG

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)

Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

• Medical imaging AI
• Radiology diagnostics
• Chest X-ray analysis
• Clinical decision support
• AI diagnostic platform

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI Diagnostic Software Licensing: Enterprise licensing of imaging AI solutions to hospitals and radiology providers. Deployment via NHS AI Diagnostic Fund and direct institutional procurement suggests recurring subscription or contract-based revenue model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Annalise.ai develops and licenses AI diagnostic software for chest X-ray interpretation, identifying emergent, incidental, and lung-cancer-related findings to support radiologist triage and worklist prioritization. The platform is deployed across NHS England trusts and other healthcare institutions globally, processing millions of chest X-rays annually. It operates as part of the consolidated Harrison.ai Radiology brand, which unifies radiology AI offerings under a single portfolio.

Product overview

Annalise.ai offers a chest X-ray AI diagnostic platform as part of the Harrison.ai Radiology portfolio. The solution provides AI-powered chest X-ray interpretation and triage capabilities deployed across NHS trusts in the UK. The product identifies findings in chest radiographs and supports early lung cancer detection, with the technology unified under the Harrison.ai Radiology brand following Harrison.ai's consolidation of its radiology AI solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Annalise.ai Chest X-ray Platform AI diagnostic tool for chest X-ray interpretation that aids in early lung cancer detection and general radiological findings identification. It is deployed across NHS England trusts through the AI Diagnostic Fund, supporting the diagnosis of 2.8 million chest X-rays annually, and is intended for hospital radiology departments and imaging networks.

Quantifiable outcome

• 45% improvement in diagnostic accuracy
• +6 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

One partnership is on record.

• I-MED RadiologycoreStrategic or Co-development Partner · 31 July 2025Data sharing partnership for AI model training. I-MED shared patient data with Harrison.ai and Annalise.ai for training AI diagnostic models. Australian Privacy Commissioner investigated and concluded data was adequately de-identified, allowing continued use without regulatory action.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Qure.ai: India-based medical imaging AI company with chest X-ray, head CT, and tuberculosis screening products. Direct competitor in NHS England AI deployments and APAC public health markets.
• Lunit: South Korean AI company whose flagship Lunit INSIGHT CXR analyzes chest X-rays for lesion detection. Competes head-to-head with Annalise.ai in CXR triage and lung cancer screening use cases.
• Aidoc: Israel-based imaging AI vendor offering a broad suite of triage and notification algorithms across CT and X-ray, frequently deployed alongside NHS and large hospital systems. Direct competitor in enterprise radiology AI workflows.
• Oxipit: Lithuania-based AI company focused on chest X-ray diagnosis and autonomous reporting. Direct competitor in European CXR AI deployments and lung cancer/tuberculosis screening.
• VUNO: South Korean medical AI company with chest X-ray products (VUNO Med-Chest X-ray) and other diagnostic algorithms. Comparable CXR AI competitor with regulatory clearances in multiple markets.
• Delft Imaging: Netherlands-based health technology company providing AI-enabled chest X-ray solutions, particularly for tuberculosis screening in low- and middle-income countries. Comparable in CXR AI and public health deployments.
• Zebra Medical Vision (now Nanox.AI): Imaging AI platform acquired by Nanox, offering AI algorithms for chest, CT, and mammography across enterprise health systems. Competitor in multi-modality radiology AI for hospitals and radiology groups.

Broad incumbents

• GE HealthCare: Global imaging equipment and enterprise PACS vendor embedding AI into CT, X-ray, and Edison platform. Competes with Annalise.ai via bundled AI and procurement incumbency in large hospital systems.
• Philips: Provides enterprise imaging, PACS, and IntelliSpace AI platform with embedded radiology AI tools. Incumbent imaging vendor that increasingly bundles AI capabilities, competing with Annalise.ai for hospital budgets.
• Siemens Healthineers: Operates AI-Rad Companion and syngo.via platforms offering AI-augmented radiology across modalities. Broad incumbent that competes with Annalise.ai by integrating AI into installed imaging bases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/annalise_ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Annalise.ai